The Stories That Made Us

Five stories

• Story 01

  When 50 sites needed to go live in 10 days, we didn't ask for more time.

  View story →Close story ↑

  A technician flew from Paris. Equipment shipped from the US. Every site in Japan opened on schedule. This is how it happened.

  Fifty investigator sites. Four hundred ABPMs. Fifty laptops. Ten business days.

  When one of the world's largest CROs came to us with those numbers, the timeline wasn't a suggestion; it was the condition. A major multi-site cardiovascular trial was ready to launch across Japan, and every single site needed to be equipped, calibrated, and patient-ready before the first protocol visit. There was no buffer. No plan B. And no local inventory in Japan capable of meeting the demand at that scale.

  Most suppliers would have started a conversation about what was realistic. We started a different conversation: about what needed to happen, and how fast we could make it happen.

  The challenge wasn't just the numbers. It was the geography, coupled with the need to deploy rapidly while ensuring full compliance with local regulations.

  Japan is one of the most demanding markets in the world for clinical trial equipment deployment. Import regulations are strict. Local calibration certification is mandatory. Sites expect Japanese-speaking support. And the consequences of a compliance gap however small, can hold an entire study.

  We had built for this. Quipment operates a registered local entity in Japan, with Japanese-speaking teams in direct contact with investigator sites, local calibration infrastructure, and import/export capabilities developed over years of operating in the market. What we didn't have and needed immediately was inventory at scale. Our stock was in the US.

  →We shipped it the same day.

  On March 4th, our expert landed in Tokyo.

  While devices were being released from our US inventory and dispatched toward Japan, we made another call: to deploy one of our biomedical experts from our Technical Service Center in France directly to Japan. On the ground. In person. There to reinforce local teams, absorb any technical complexity that arose, and make sure nothing slipped through the gap between remote coordination and on-site reality.

  In parallel, a dedicated project manager took charge of the entire operation running daily communication with the client's teams, monitoring site activations in real time, adjusting logistics plans as activations were confirmed, and coordinating internal teams across three time zones. Orders were dispatched daily, each one trackable in real time on Quipsite, our proprietary web platform. We also rapidly invested in additional production and testing capabilities to absorb the scale of what we were deploying.

  We did not raise the question of extra costs with the client. That wasn't the conversation we were in.

  March 13th. All 50 sites. Patient-ready.

  Ten business days after the clock started, every investigator site in Japan was active. Every ABPM deployed, calibrated, and certified. Every calibration certificate available in real time on Quipsite accessible to the sponsor, the CRO, and the sites themselves, without a single document to chase.

  The trial launched on schedule. Not approximately on schedule. On schedule.

  What this case says about how we work.

  This wasn't a story about having the right devices in the right place at the right time though we did. It was a story about what happens when a partner refuses to treat "impossible" as a complete sentence.

  We flew someone to Tokyo because the situation needed it. We shipped from the US because waiting for local stock wasn't an option. We rapidly mobilized our project management team because the client needed a single point of accountability, not a chain of handoffs. And we absorbed the operational complexity the import/export, the calibration, the traceability, the daily coordination so that the client's only job was to watch their sites go live.

  →One by one. On time. All fifty.

  Services demonstrated

  • Japanese local presence and registered entity
  • Import/export capabilities
  • Local calibration infrastructure
  • High-level project management
  • Real-time shipment tracking
  • Quipsite traceability platform
  • In-house biomedical expertise Regulatory compliance management across local requirements
  • Flexibility and client dedication
• Story 02

  3 months. Zero emails. Full trust.

  View story →Close story ↑

  A confidential program. A supply chain built from scratch. A partner who made it look effortless.

  Three months from contract signature to go-live. A brand-new, heavily regulated device with no established supply chain. Strict confidentiality requirements that ruled out standard email entirely. And a strategic program in the diabetic/obesity space that could not, under any circumstances, fail.

  When a global pharmaceutical sponsor came to us, they weren't looking for a vendor. They were looking for a partner they could trust completely one capable of operating at the highest level of discretion, speed, and operational precision simultaneously.

  →We said yes. Then we got to work.

  First, we built the infrastructure.

  Standard email was off the table. So, before anything else, we built a dedicated secure digital platform: ISO-aligned, purpose-built for cross-sharing information between the sponsor's authorized contacts and our teams. Developed in record time. Operational before the first device moved.

  Access to confidential trial discussions was restricted to authorized participants only. Internally, we implemented strict confidentiality protocols that ensured the program's existence let alone its details never traveled beyond the people who needed to know.

  A single certified project manager was assigned as the sponsor's sole point of coordination. One person. One number. One accountability. The governance structure adapted to the program's evolving needs running up to three coordination calls per week when the pace demanded it.

  Then, we built the supply chain.

  The devices required for the study were new, complex, and heavily regulated. No existing supplier relationship. No established logistics model. No precedent for international deployment at this scale.

  →We built it anyway.

  Our in-house experts in sourcing, regulatory affairs, import/export, and medical device compliance worked in parallel to construct a full end-to-end supply chain from manufacturer to investigator site across multiple international markets. Every regulatory approval obtained. Every import document in place. Every market cleared before the first shipment moved.

  We also made a decision that would prove critical to the timeline: leveraging our fleet of thousands of reprocessed devices and our in-house reprocessing capabilities to deploy alongside new equipment. The result was twofold: hyper-rapid delivery timelines that new devices alone could not have achieved, and a meaningfully reduced carbon footprint for the trial.

  The entire process appeared seamless to the sponsor. That was the point.

  Every SIV date met. Zero defects.

  From the first trial won to go-live— three months, as committed. Every shipment compliant and fully functional. Zero device failures from start to finish. Confidentiality maintained throughout.

  The sponsor sent a formal message requesting that Quipment's teams be recognized for their exceptional work. It became an occasion for celebration on both sides.

  →And then they came back with more trials.

  What this case says about how we work.

  The trial demanded everything simultaneously: speed, discretion, technical complexity, regulatory precision, and the ability to build something entirely new under extreme time pressure. There was no template to follow. No existing playbook to consult.

  What made it possible was not any single capability it was the combination of all of them, held together by a project management structure designed to absorb complexity before it reached the client. The sponsor's job was to run their program. Our job was to make sure they never had to think about the equipment.

  →They didn't.

  Services demonstrated

  • Confidential program management
  • Secure digital platform
  • PMI-certified project management
  • End-to-end supply chain construction
  • Regulatory affairs and import/export expertise
  • Reprocessed device fleet
  • Sustainability
  • International deployment capabilities
• Story 03

  When the world ran out of stock, the trials didn't stop.

  View story →Close story ↑

  The pandemic hit everyone. The CRO's studies kept running. Here's what happened behind the scenes.

  In the spring of 2020, the global supply chain for medical equipment didn't slow down. It collapsed. Infusion pumps. Thermometers. Data loggers. -80°C freezers. The devices most critical to COVID-19 treatment and research were simultaneously the most impossible to source, stripped from the market faster than any manufacturer could replenish them.

  Clinical trials across the industry began to stall. Sites couldn't get equipment. Studies were suspended. Sponsors were making impossible calls about which trials could continue and which couldn't.

  →The CROs studies kept running. Every one of them.

  We were in the middle of the same crisis.

  This matters, because it would be easy to tell this story as if Quipment was somehow untouched by what was happening. We weren't. Like every organization in early 2020, we were adapting to the new working methods, supporting colleagues affected by the illness, safeguarding the health and well-being of our teams, and our own sourcing difficulties.

  What we chose to do in the middle of all of that was enter into full crisis-mode partnership with our client.

  We mobilized every available sourcing channel simultaneously. Our own supplier network. Client relationships. Alternative device references. Direct supplier contacts on both sides. We didn't wait for the situation to stabilize. We moved before the shortage became a crisis for the CRO, because by then it would have been too late.

  We built a dedicated stock worth several million euros.

  The commercial model we designed was built for simplicity and flexibility. A single stock reservation structure allowed our client to draw down inventory study by study no complicated allocation process, no inter-study competition for limited resources. A dedicated stock management and reporting system tracked allocation across studies in real time.

  Every pallet was physically stored at Quipment's facilities. At no cost to the client.

  And when the program ended and some items remained unused, we bought them back. Zero waste. Full asset utilization. No loose ends.

  The result went beyond keeping trials running.

  The CRO's studies continued without interruption and without a single equipment failure throughout the pandemic. While sponsors were facing shortages across the board, our client had stock and a partner ready to dispatch immediately.

  That operational resilience became a commercial asset. Our client's credibility with sponsors was significantly strengthened during the crisis at precisely the moment when reliability was the rarest commodity in the industry. New studies were won directly as a result.

  What this case says about how we work.

  The easy version of this story is: we had stock when others didn't. But that misses what happened. We made a decision under our own operational pressure, during the most disruptive period in modern clinical research to prioritize a partner's continuity over our own convenience. We stored millions of euros of equipment at our own cost. We absorbed the complexity so our clients could focus entirely on their studies.

  →That's not logistics. That's partnership.

  Services demonstrated

  • Crisis procurement
  • Inventory management and storage
  • Flexible stock reservation model
  • Real-time allocation tracking
  • Return management
  • Partnership relations
  • Operational resilience
• Story 04

  1,500 laptops. 10 countries. One of the worst semiconductor shortages in history.

  View story →Close story ↑

  Our client needed devices that didn't exist on the market. We found them anyway.

  The brief was straightforward on paper. Deploy 1,500+ laptops fully configured with a custom software stack across 10 countries within a 9-month window for a major international clinical trial. Standard large-scale technology deployment for a top-tier pharma sponsor.

  Except it wasn't 2019. It was the middle of the global semiconductor crisis. And laptops, at that moment, were among the scarcest commodities on the planet.

  Our client needed a partner who could do what the market said couldn't be done.

  We built a task force from scratch.

  There was no existing playbook for what this deployment required not at this scale, not under these sourcing conditions. So the first thing we did was build the team that would write one.

  A dedicated task force: a specialist buyer, a supply planner, and a laptop specialist recruited specifically for this program. Three people whose only job, for the duration of the deployment, was to find a solution.

  They started with sourcing which meant going everywhere at once. Quipment's international footprint gave us access to supply channels that single-market operators simply couldn't reach. We leveraged supplier relationships across geographies, chased every available allocation, and built a procurement pipeline capable of delivering at volume when the global market was running on empty.

  Then we configured every single one.

  Sourcing 1,500+ laptops during a semiconductor crisis was only half the challenge. Every device also needed to be configured with the full software stack required for the study a customized MDM (Mobile Device Management) solution tailored precisely to the trial's specifications.

  That work happened in-house. Our technical teams configured and provisioned each device individually, ensuring that every laptop arriving at an investigator site in any of the 10 countries was identical in setup, compliant with the study requirements, and ready to use from the moment it was unpacked.

  All 10 countries. On time.

  Despite one of the worst global semiconductor shortages in recent history, every laptop was deployed and the study launched on schedule. Across 10 countries. Over 9 months. Without a single country falling behind.

  →The trial proceeded without interruption.

  What this case says about how we work.

  When the market says a problem can't be solved, we treat that as a procurement challenge, not a conclusion. We built a specialist team, developed a custom technical solution, and leveraged a global sourcing network all for a single study, because that study needed it.

  Scale and complexity don't change commitment. They just raise the stakes.

  Services demonstrated

  • Large-scale procurement under shortage conditions
  • International sourcing network
  • Custom MDM configuration
  • End-to-end deployment across multiple countries
  • Dedicated task force model
  • Technical expertise
  • Flexibility and agility
• Story 05

  No playbook existed for this trial. So we wrote one.

  View story →Close story ↑

  The first decentralized direct-to-patient oncology trial in the US. No template. No precedent. No problem.

  When a sponsor approaches you with a trial format that has never been done before in your market, there are two responses. The first is to explain, carefully, all the reasons why it's complicated. The second is to ask what needs to be built.

  →We asked the second question.

  The brief had no precedent.

  A colorectal cancer study. Decentralized trial model. Kits delivered directly to patients at home across the United States. Full CFR 21 Part 11 compliance required end to end. A custom patient kit delivery logistics model that didn't exist. A dedicated software platform that needed to be built from scratch. And a timeline that left no room for iteration.

  There was no off-the-shelf solution. No existing infrastructure to adapt. No industry template to borrow from. This was, genuinely, one of the earliest direct-to-patient clinical trials of its kind in the US.

  The sponsor needed a partner capable of designing the entire solution, not just executing a piece of it.

  We designed it from the ground up.

  Our team led by Josh, Head of our Technical Service Center, as direct client interface throughout approached the project as an engineering challenge as much as a logistics one. Every dimension of the solution needed to be built simultaneously and in alignment: regulatory, operational, technical, and clinical.

  The software platform came first. We developed a dedicated system built for full CFR 21 Part 11 compliance the FDA's regulatory framework for electronic records and signatures in clinical trials. Not adapted from an existing tool. Purpose-built for this study, from scratch.

  Then the logistics model. A patient-level kit delivery system designed around the specific requirements of a home-delivery oncology trial: the right devices, the right consumables, the right packaging, the right traceability all the way to the patient's doorstep. A dedicated operational team managed the entire chain, from kit assembly to last-mile delivery, ensuring that nothing was lost in handoffs between functions.

  Throughout, Josh ensured alignment across clinical, regulatory, and operational dimensions so that every decision made in one domain was immediately reflected in the others.

  The trial launched. One of the first of its kind.

  Successfully. On time. With a solution that had been designed, built, and deployed in a market where no one had done it before.

  What this case says about how we work.

  Decentralized and direct-to-patient trials are no longer the future of clinical research. They are its present. But the infrastructure to support them the logistics models, the compliance frameworks, the software platforms is still being built, market by market, trial by trial.

  We built ours for this trial. And in doing so, we demonstrated something we believe defines us as a partner: when the situation requires a new solution, we don't look for the nearest existing template. We design what the trial actually needs.

  →From scratch. If necessary.

  Services demonstrated

  • Direct-to-patient logistics
  • CFR 21 Part 11 compliant software development
  • Custom kit delivery model
  • End-to-end operational ownership
  • Regulatory expertise
  • IT development
  • Clinical trial expertise
  • Agility and hands-on execution